Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oral anticancer therapies designed to prevent cancer cell proliferation and angiogenesis by inhibiting proteins that signal or support tumor growth in the United States and internationally. The company’s product includes Nexavar, an orally active agent to operate through dual mechanisms of action by inhibiting angiogenesis and the proliferation of cancer cells. Its Nexavar inhibits the signaling of VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-ß, key receptors of Vascular Endothelial growth factor, and Platelet-Derived growth factor. Nexavar also inhibits other kinases involved in cancer, such as KIT, FLT-3, and RET. The company also develops a Phase I clinical trial product, PD 332991, a small molecule inhibitor of cyclin-dependent kinase 4 for the treatment of multiple cancer types. It has collaboration agreements with Bayer Pharmaceuticals Corporation to discover, develop, and market compounds that inhibit the function, or modulate the activity of the RAS signaling pathway to treat cancer and other diseases; and Warner-Lambert Company to discover and commercialize small molecule drugs that restore control of, or intervene in the misregulated cell cycle in tumor cells. The company was founded in 1992 and is headquartered in Emeryville, California.